This infographic and the studies discussed were funded by AstraZeneca. This content is intended for US Healthcare Professionals only.
TOURMALINE evaluated the safety and efficacy of first-line durvalumab combined with one of seven gemcitabine-based chemotherapy regimens in a near-real-world advanced biliary tract cancer (aBTC) population, including participants with poor prognosis. This infographic explores the primary analysis and what it means for a broader aBTC population.
You will learn:
- How safety held up across seven different gemcitabine-based regimens
- What happened to infusion-related reactions when durvalumab infusion time was cut from 60 to 30 minutes
- What the efficacy findings indicate about durvalumab combined with these regimens
- Whether the primary analysis supports this approach in participants with less favorable prognosis
